Transplanting insulin-making cells from fresh cadavers into diabetes patients can reverse the disease, but the procedure has been too costly for widespread use. Scientists have now developed a less costly version of the procedure.
In a trial of cell transplants in eight patients, five were free of disease 1 year after their transplants, a success rate comparable to that of previous cell-transplant trials. However, in those earlier trials, every patient received an infusion of cells from each of two or occasionally more cadavers. Each infusion costs about $75,000, including the first year of follow-up treatment. In the new trial, the transplant cells for each patient came from only one cadaver—a cost-saving procedure that could make cell transplants more commonplace, says study coauthor Bernhard J. Hering of the University of Minnesota in Minneapolis.
After a transplant, the insulin-making pancreas cells from cadavers take up residence in the liver and start producing insulin. For the three patients with unsuccessful outcomes in the recent trial, the transplanted cells didn't manage to establish themselves, Hering says. The immune systems of these three individuals probably rejected the pancreas cells, he adds.
To find the best protocol for the procedure, Hering and his colleagues used a combination of antirejection drugs that didn't include steroids, which often have unpleasant side effects. Rather, the patients received etanercept, an anti-inflammatory arthritis medication, and two other drugs that fight rejection, the researchers report in the Feb. 16 Journal of the American Medical Association.
Bernhard J. Hering
Department of Surgery
University of Minnesota
Mayo Mail Code 195
420 Delaware Street, S.E.
Minneapolis, MN 55455
Goss, J.A., et al. 2002. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 74(Dec. 27):1761-1766. Abstract.
Hirshberg, B., et al. 2003. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: The National Institutes of Health experience. Diabetes Care 26(December):3288-3295. Available at [Go to].
Shapiro, A.M., et al. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine 343(July 27):230-238. Available at [Go to].